The state and consequences of dermatology drug prices in the United States
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
UMass Chan Affiliations
Division of Dermatology, Department of MedicineDocument Type
EditorialPublication Date
2016-09-01Keywords
coinsurancesdrug pricing
formulary tiering
generic drugs
out-of-pocket costs
pharmacy benefit managers
prior authorizations
Dermatology
Pharmacoeconomics and Pharmaceutical Economics
Metadata
Show full item recordAbstract
In 2014, Medicare expenditures increased 12%, the largest increase reported since 2002, resulting in major concerns by both patients and physicians. Although costs are rising for both specialty drugs and generic medications,out-of-pocket costs, restrictive formularies,and health plan bureaucracies are limiting patients' access to necessary medications. In response, the Regulatory Policy Committee of the American Academy of Dermatology (AAD)/Association (AAD/A) convened a Task Force on Drug Pricing and Transparency. This editorial summarizes the issues addressed by the task force along with relevant AAD/A policy.Source
J Am Acad Dermatol. 2016 Sep;75(3):603-5. doi: 10.1016/j.jaad.2016.03.053. Epub 2016 Jul 13. Link to article on publisher's siteDOI
10.1016/j.jaad.2016.03.053Permanent Link to this Item
http://hdl.handle.net/20.500.14038/29074PubMed ID
27423978Notes
Full author list omitted for brevity. For full list of authors see article.
Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.jaad.2016.03.053